pembrolizumabLenvatinibMerkel cell carcinomaH. Lee Moffitt Cancer Center & Research InstituteMerckMCCNCI
…treatment samples and in responders.Conclusions Lenvatinib plus pembrolizumab demonstrated encouraging efficacy when used as neoadjuvant ther…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 541–600 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
N-Acetyl Cysteine7PPIs7Streptozotocin7fondaparinux7high-dose corticosteroids7hydroxyurea7naltrexone7tyrosine kinase inhibitors7vaccines7SGLT-2i6Glipizide6BLV6Varenicline6Camrelizumab6Cancer Drugs6Benzene6Doxy-PEP6SGLT-2is6Aprepitant6DEX6Dostarlimab6T-DXd6Azacitidine6Esketamine6NAC6Fidaxomicin6ITM6Minocycline6N-acetylcysteine6pMDIs6NBCA6Clofazimine6Filgotinib6Ravulizumab6Atomoxetine6Methylphenidate6amoxicillin-clavulanate6Acetylcysteine6Triamcinolone6anti-PD16Nitrous oxide6Octreotide6injectate6IL-1β6Lenalidomide6OAC6Venetoclax6antihypertensive drugs6n-BCA6Anti-TNF6Golimumab6Placebo6aripiprazole6b/tsDMARDs6Lansoprazole6MDPV6Mitomycin C6Nalbuphine6PCSK9 inhibitors6Sodium-Glucose Co-Transporter 2 Inhibitors6
Articles mentioning drugs
10,506 articles · page 250 of 876aspirinacetylsalicylic acidacute coronary syndromeinfluenzaAmsterdam UMCstandard therapycommunity-acquired pneumoniaACS
… 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients.…
Igrituximabmultiple sclerosisSDRIFEsecondary immunodeficiency
…sclerosis. 3 days after receiving her first dose of intravenous Ig, she developed a pruritic rash in her intertriginous regions of…
pembrolizumabHCW11-040InvivoGencancer
…gainst human SW1990 pancreatic tumor cell line when compared to pembrolizumab. HCW11-040 was also found to neutralize the immunosuppresivenes…
anti-PD-L1 scFvPD-L1-blocking scFvB7-H3OsteosarcomaPurdue Center for Cancer ResearchPurdue College of PharmacyPurdue UniversityOSNational Cancer InstituteV Foundation for Cancer Research
…red NK cells to express a B7-H3.CAR alongside a tumor-cleavable anti-PD-L1 scFv demonstrated significantly enhanced cytotoxicity against OS cel…
temozolomideTMZmPIIBGBMGlioblastoma
…rammed iAPCs and GFP-transduced controls were then treated with temozolomide (100µM, 72h) or TTFields (200kHz, 1.5V/cm, 72h), and pyroptosis…
pembrolizumabnivolumabipilimumabrelatimabmelanomaLifespanBrown University Health
…de combination ipilimumab and nivolumab, nivolumab monotherapy, pembrolizumab, and combination relatimab and nivolumab. Regarding hospitaliza…
PD-L1Agency for Science, Technology and ResearchZeiss
…112-pixels) to train a vision transformer model (ViT-B/16)6 for PD-L1 binary classification (figure 1).Results Our Pix2Pix GAN model …
epcoritamabteclistamabelranatamabTCE
…ytotoxicity data from three TCEs (teclistamab, elranatamab, and epcoritamab). Hypothetical experiments were simulated to explore possible i…
trastuzumabHer2sacituzumabcetuximabTROP2EGFRcancerNRG mice
…ROP2, or EGFR Boosters demonstrated superior tumor control than trastuzumab, sacituzumab, or cetuximab analogue treated mice respectively. …
ZoldonrasibSotorasibSMITRIM7
…d outperformed other KRAS pathway inhibitors like Sotorasib and Zoldonrasib, without selectivity to specific KRAS mutations. TRIM7 specific…
APVO451solid tumorsovarian cancers
…ter than a traditional T-cell engager. The CD40-directed arm of APVO451 led to the induction of IL-12 secretion and upregulation of CD8…